Navigation Links
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
Date:11/2/2009

FREMONT, Calif., Nov. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will present a case history of QPI-1002, the first systemically administered synthetic siRNA, at the Joint Symposium of the 5th Annual Meeting of Oligonucleotide Therapeutics Society and the 19th Antisense Symposium in Fukuoka, Japan, November 3-6, 2009. The company also announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, will participate in the RNAi for Developing Targeted Therapeutics track at this year's CHI Discovery on Target Conference in Boston, November 2-4, 2009.

Dr. Thompson's presentation will be part of a session titled, "Clinical Studies and Therapeutic Development," which will be held on Thursday, November 5. The case study on QPI-1002 will detail Quark's progress in its independent development of the first systemic administration of a synthetic siRNA in humans, results from Quark's IND-enabling efficacy and toxicology studies and the largest cGMP manufacture of synthetic siRNA of its time. Dr. Feinstein's presentation, titled "Use of siRNA for Amelioration of Aseptic Lung Inflammatory Conditions," will take place on Wednesday, November 4 and will present Quark's preclinical studies for aseptic lung inflammation.

Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "Drs. Thompson and Feinstein's presentations demonstrate Quark's leadership and continued innovation in the discovery and development of siRNA therapeutics. Quark's strength in preclinical discovery has promoted development of a robust pipeline that provides our company with growth opportunities within a broad range of therapeutic areas. We are nicely positioned to progress our clinical stage drug candidates, including t
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
2. Quark Pharmaceuticals Presents at Asia TIDES Conference
3. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... 2014 /PRNewswire-iReach/ -- This is a professional ... Chinese Vardenafil (CAS 224785-90-4) industry. The report ... (CAS 224785-90-4) including its classification, application and ... and China,s top manufacturers of Vardenafil (CAS ... value, cost, gross margin and market share ...
(Date:7/25/2014)... "Australia Capsule Endoscopy Systems Market Outlook to 2020″, provides ... market. The report provides value, in millions of US ... dollars) within market segments: Photo - ... , Capsule Endoscopy Data Recorders , Capsule Endoscopy ... shares and distribution shares data for each of these ...
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
Breaking Medicine Technology:Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3
... N.J., Sept. 29, 2011 Innophos Holdings, Inc. (NASDAQ: ... had declared a third quarter dividend of $0.25 per share ... 31, 2011 to stockholders of record as of the close ... Innophos Holdings, Inc.Innophos is the leading North American producer of ...
... Calif., Sept. 29, 2011 Meg Porfido, former chief ... named to the Board of Directors for Kaiser Foundation ... "The addition of Meg Porfido to our Board will ... our Board of Directors," said George C. Halvorson, chairman ...
Cached Medicine Technology:Kaiser Foundation Hospitals and Health Plan Appoints Meg Porfido to Its Board of Directors 2Kaiser Foundation Hospitals and Health Plan Appoints Meg Porfido to Its Board of Directors 3
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
(Date:7/28/2014)... Research into improving treatment for patients with one of ... 810,000 funding boost. , Chronic obstructive pulmonary disease (COPD) ... cause breathing difficulties due to long-term damage to the ... for 10 per cent of all hospital admissions in ... readmitted to hospital after they are discharged. ...
(Date:7/28/2014)... Malibu, CA (PRWEB) July 28, 2014 ... upon us, it is welcome news that a ... effective than current protection is under development by SunSeeker ... by NASA to protect spacecraft from the extreme heat ... protection to both firefighters and homes. , “Our firefighters ...
(Date:7/28/2014)... 28, 2014 Drorit Silverman, a professional ... plans to raise investment capital through her crowd funding ... in the United States. , According to a statement ... fitness centers provide a great window of opportunity for ... space. In addition to this, Silverman looks at the ...
(Date:7/28/2014)... (Boston)-- Researchers from Boston University School of Medicine (BUSM) ... increase the risk of developing Alzheimer,s disease (AD). The ... new drug treatment options that target PLXNA4 specifically. These ... , AD is the most frequent age-related dementia affecting ... 65 and older, and more than 40 percent of ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Researchers identify potential biomarker for AD 2
... and Treatment Centers Seek Competitive Advantage by Leveraging ... to make ends meet, the ability to do ... gain efficiencies comes from two converging market forces: ... recession-proof healthcare industry, and the national push to ...
... will be made available closer to the meeting date. ... the meeting as well as during the meeting. , ... Council of the National Academy of Sciences. The Society,s ... and to encourage applications of research findings. Its membership ...
... QC, April 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... the results of its recently completed North American ... of tramadol and acetaminophen (study 06CCL3-001). , Study ... that compared the efficacy and safety of Labopharm,s ...
... connect, exchange information and ,speak, HL7. , ... Toronto, ... - a core need in modern healthcare - has never been ... HL7 Interface Engine . This easy-to-use yet powerful tool, ...
... through common symptoms during pregnancy, such as morning sickness, fatigue and weight ... when they come. At Gurgle, we offer a guide to women in ... , ... London, England (PRWEB) April 2, 2009 -- Around half of ...
... NY -- Biomedical informatics researchers at Mayo Clinic ... the newly founded Open Health Natural Language Processing ... space to promote past and current development efforts, ... records. , As part of the launch, Mayo ...
Cached Medicine News:Health News:Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies 2Health News:Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies 3Health News:Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation 2Health News:Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation 3Health News:Talking Iguana - Helping the Healthcare Sector Speak HL7 2Health News:Talking Iguana - Helping the Healthcare Sector Speak HL7 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Mayo Clinic and IBM host medical language initiative 2Health News:Mayo Clinic and IBM host medical language initiative 3Health News:Mayo Clinic and IBM host medical language initiative 4
Outer diameter 8.0 mm, with graduation....
Greenberg micro instrument holder is a flexbar arm used to hold micro instruments used repeatedly within retracted fields. Holds instruments with shafts up to 1/8 in diameter....
Greenberg universal retractor case, with four compartments to hold various components....
Length-9 (229 mm) Tapered retractor blades....
Medicine Products: